Why Meridian Bioscience's Shares Are Rising Today?

Loading...
Loading...

Meridian Bioscience Inc VIVO has posted Q1 FY22 sales of $88.2 million, down 4.9% Y/Y, sharply beating the consensus of $70.29 million.

  • Diagnostics segment net revenues were up 10% Y/Y to $33.20 million, while Life Science segment net revenues were down 12% to $55.14 million.
  • The diagnostics segment experienced a 4% increase in molecular products sales, and non-molecular assay products revenues increased 11% despite the impact of the LeadCare product recall and the pausing of sales in mid-August 2021. 
  • The Life Science segment experienced a dramatic shift in net revenues mix from molecular products (32% decrease) to immunological products (43% increase), driven by the demand for COVID-19 rapid antigen tests relative to molecular test demand experienced in fiscal 2021.
  • Adjusted operating income margin of 23%, down from 40% in the prior year.
  • The Company held $72.7 million in cash and cash equivalents.
  • Adjusted EPS reached $0.35, down from $0.65 a year ago, beating the consensus of $0.25.
  • Guidance: Meridian Bioscience expects FY22 sales of $315 million - $330 million better than previous guidance of $285 million - $300 million and above the consensus of $288.8 million.
  • The Company forecasts Diagnostics sales of $145 million - $150 million, and the Life Science segment of $170 million - $180 million, up from previous guidance of $140 million - $150 million.
  • For FY22, VIVO sees an adjusted operating margin of 21% - 23%.
  • The Company raised adjusted EPS guidance to $1.10 - $1.30, from $0.98 - $1.08.
  • Price Action: VIVO shares are up 6.62% at $22.80 during the market session on the last check Friday.
Loading...
Loading...
Posted In: EarningsLong IdeasNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...